Drugging the p53 pathway: understanding the route to clinical efficacy

作者：Hoe Khoo Kian; Verma Chandra S; Lane David P^*

来源：Nature Reviews Drug Discovery, 2014, 13(3): 217-236.

DOI：10.1038/nrd4236

The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more than half of all human tumours carrying mutations in this particular gene. Intense efforts to develop drugs that could activate or restore the p53 pathway have now reached clinical trials. The first clinical results with inhibitors of MDM2, a negative regulator of p53, have shown efficacy but hint at on-target toxicities. Here, we describe the current state of the development of p53 pathway modulators and new pathway targets that have emerged. The challenge of targeting protein-protein interactions and a fragile mutant transcription factor has stimulated many exciting new approaches to drug discovery.

• 出版日期2014-3